Tamoxifen tam

MCF7 human breast cells were obtained from American Type Culture Collection (ATCC) in Manassas, VA, USA. Cells were cultured in 75 cm tissue culture flasks (Corning) in a humidified atmosphere (5% CO₂) at 37 °C. MCF7 cells were cultured in DMEM high glucose media (Gibco, Grand Island, NY, USA) with 10% FBS and penicillin–streptomycin (Gibco). Doxorubicin hydrochloride (DOX; Pfizer, Manhattan, NY, USA), tamoxifen (TAM; Cayman Chemical, Ann Arbor, MI, USA), APCIN (Sigma), Mad2-Inhibitor 1 (Cayman Chemical), nocodazole (Sigma), and thymidine (Sigma-aldrich cat # t1895) were acquired from the indicated providers. All treatment compounds were reconstituted in dimethylsulfoxide (DMSO). Drug treatments were applied at the concentrations and times as indicated. Flow cytometry was performed as described previously [32 (link)].

To induce Cre recombination, mice were intraperitoneally injected with 1.5 mg/kg body weight of tamoxifen (TAM; Cayman Chemical) dissolved in sunflower oil (Sigma-Aldrich) for 2 consecutive days. For Cre induction in vitro, cells were treated with 2 µM 4-hydroxy-Tamoxifen (4-OHT, Sigma-Aldrich).